Document › Details
Rigontec GmbH. (2/4/15). "Press Release: Rigontec GmbH Appoints Dr. Christian Schetter as CEO". Bonn.
|Organisation 2||Neovii Biotech GmbH|
|Group||Neopharm (IL) (Group)|
|Product||cancer immunotherapy (immuno-oncology)|
|Product 2||oligonucleotide drug|
|Person||Schetter, Christian (Rigontec 201501– Managing Director before Fresenius Biotech GmbH + Coley GmbH)|
|Person 2||Gardner, Chris (Consilium 201507– Partner before since 2003 at Citigate Dewe Rogerson London)|
Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces the appointment of Dr. Christian Schetter as CEO.
Dr. Schetter joins Rigontec from Neovii Biotech GmbH, previously Fresenius Biotech GmbH, where he was President & CEO. During his tenure one antibody product was brought to market and the indication for another product expanded. Dr. Schetter was instrumental in selling Fresenius Biotech to the Neopharm Group to form Neovii Biotech and positioning it as a successful standalone business.
Prior to joining Fresenius, Dr. Schetter was Senior Vice President, European Operations of Coley Pharmaceutical Group, Inc, a pioneer in the development of immunostimulatory oligonucleotides, and served as Managing Director of Coley GmbH. He was part of the leadership team which built Coley Pharmaceuticals from inception through multiple financing rounds, a NASDAQ IPO and, following a number of significant pharma deals, to a trade sale to Pfizer in 2007.
Dr. Schetter joined Coley from the Max Planck Institute in Martinsried, Germany. He received his undergraduate degree and PhD from the University of Cologne and did postdoctoral research in oncology and virology at the Scripps Research Institute in La Jolla, California. He is a member of the Executive Board of BIO Deutschland, the German biotech business association.
Dr. Schetter said: “I am convinced immunotherapy will become one of the key treatment options for cancer patients and Rigontec’s technology has the potential to be a major force in this space. Rigontec’s proprietary structures target the RIG-I receptor in a highly specific and effective manner leading to immunogenic cell death of tumor cells, making the tumor microenvironment foster anti-tumor immunity, and establishing long lasting systemic immune memory. This is a potentially revolutionary technology and I look forward to working with the founders, investors and management to put in place the strategy and team to deliver on its promise.”
Gunther Hartmann, co-founder and Chairman of the Board of Rigontec, said: “We are delighted to welcome Christian as CEO of Rigontec. He has exceptional experience in the development of innovative technologies, including immune products, great specific expertise in immunostimulatory oligonucleotides, a proven track record in fundraising and corporate development, and an academic background which is highly relevant to our business. We have no doubt he will play a significant role in advancing our technology and ensuring that ultimately its benefits are available to cancer patients.”
Dr. Christian Schetter
Tel: +49 15146675978
Citigate Dewe Rogerson
Dr. Chris Gardner / Dr. Mark Swallow
Tel: +44 (0) 207 638 9571
Record changed: 2016-06-07
More documents for Rigontec (Group)
-  Rigontec GmbH. (9/6/16). "Press Release: Rigontec Raises Additional €15M in Extended Series A to Advance Novel RIG-I Targeted Immuno-Oncology Therapeutics". Bonn, Munich & Cambridge, MA....
-  BIO Deutschland. (10/6/15). "Press Release: Biotechnology Sector Association Elects a New Board. BIO Deutschland Holds Its Twelfth General Assembly". Hanover....
-  High-Tech Gründerfonds Management GmbH. (3/24/15). "Press Release: Rigontec GmbH Raises €4.8m in a Second Closing of Its Series A Financing. Brings Series A Total to €14.25m to Advance RNA-based Immunotherapeutics for Cancer and Viral Diseases"....
-  MaK. (1/2/15). "News: Personalia. Christian Schetter wechselt zu Rigontec"....
-  High-Tech Gründerfonds Management GmbH. (10/14/14). "Press Release: Rigontec GmbH Raises € 9.45m in a First Closing of a Series A Financing Round to Advance RNA-based Immunotherapeutics for Cancer and Viral Diseases". Bonn....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to email@example.com and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)